Haleon plc releases 2024 annual report and Form 20-F

Haleon plc, a leader in consumer health with a market capitalization of $46.2 billion, announced today the publication of its Annual Report and Form 20-F for the year ended December 31, 2024. The documents provide a comprehensive overview of the company’s financial performance, including its $14.1 billion in revenue and strong gross margin of 61.9%, and were submitted to the National Storage Mechanism, making them available for public inspection. According to InvestingPro analysis, the company maintains a GOOD financial health score.

The financial details within the Annual Report have also been filed with the US Securities and Exchange Commission. Interested parties can access the report on Haleon’s website and the National Storage Mechanism’s platform. The company’s stock has shown strong momentum, delivering a 25.4% return over the past year and trading near its 52-week high of $10.80.

The report highlights Haleon’s product portfolio, which encompasses Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Other, as well as Vitamins, Minerals, and Supplements. The company’s brands, including Advil, Sensodyne, and Centrum, are noted for their foundation in science and innovation.

Shareholders wishing to obtain a physical copy of the Annual Report, which includes the complete audited financial statements, can request one from the company’s secretariat.

Looking ahead, Haleon has scheduled its Annual General Meeting for May 28, 2025. The Notice of AGM with further details will be distributed to shareholders in due time.

This news is based on a press release statement.

In other recent news, Haleon plc has finalized a significant share buyback transaction, purchasing 44,155,844 ordinary shares from Pfizer Inc. (NYSE:PFE) for approximately £170 million. This move is part of Haleon’s broader £500 million repurchase plan for 2025, initially announced in February of this year. The completion of this transaction marks Pfizer’s exit from Haleon’s shareholder base, reducing its stake from about 7.3% to zero. Concurrently, HSBC analyst Jeremy Fialko has downgraded Haleon’s stock rating from Buy to Hold, maintaining a price target of GBP4.20. The downgrade follows a 25% rise in Haleon’s share value over the past year, which has increased the forward price-to-earnings ratio. Additionally, Haleon disclosed executive share acquisitions by General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers, aligning with the company’s Share Reward Plan. In governance changes, Bryan Supran, a Non-Executive Director representing Pfizer, has stepped down from Haleon’s board after Pfizer’s stake fell below 10%. These developments reflect Haleon’s strategic maneuvers as it continues to navigate its post-demerger growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.